MicroRNA-136 promotes proliferation and invasion ingastric cancer cells through Pten/Akt/P-Akt signaling pathway

Chen,Xuyan; Huang,Zhiming; Chen,Renpin

doi:10.3892/ol.2018.7848

MicroRNA-136 promotes proliferation and invasion ingastric cancer cells through Pten/Akt/P-Akt signaling pathway

Authors:
- Xuyan Chen
- Zhiming Huang
- Renpin Chen
View Affiliations

Affiliations: Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
Published online on: January 24, 2018 https://doi.org/10.3892/ol.2018.7848
Pages: 4683-4689

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer is the fourth most common cancer and the second most frequent cause of cancer‑associated mortality in the world. Previous studies have revealed that expression levels of microRNAs (miRNAs) are associated with the initiation and progression of several types of cancer, including gastric cancer. Previous studies have demonstrated that the abnormal expression of miRNA‑136 may serve a function in the progression of several types of human cancer. However, the expression pattern of miR‑136, its functions and underlying molecular mechanisms in gastric cancer remain unresolved. In the present study, it was revealed that the expression of miR‑136 was aberrantly up regulated in gastric cancer tissues and cell lines. The suppression of miR‑136 was able to inhibit proliferation and invasion in gastric cancer cell lines. Furthermore, phosphatase and tensin homolog (PTEN) was identified as a direct target gene of miR‑136 in gastric cancer. PTEN was under expressed in gastric cancer tissues compared with non‑tumor gastric tissues, and PTEN expression was negatively correlated with miR‑136 expression. Furthermore, PTEN overexpression mimics the effects of miR‑136 knockdown on gastric cancer cells. Additionally, miR‑136 under expression decreased phospho‑(p) AKT expression, but did not affect AKT expression in gastric cancer cells. In conclusion, the data of the present study suggest that miR‑136 acts as an oncogene in gastric cancer via regulation of the PTEN/AKT/p‑AKT signaling pathway and may potentially serve as a novel therapeutic target for the treatment of gastric cancer.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Yang L: Incidence and mortality of gastric cancer in China. World J Gastroenterol. 12:17–20. 2006. View Article : Google Scholar : PubMed/NCBI
3	Guo M and Yan W: Epigenetics of gastric cancer. Methods Mol Biol. 1238:783–799. 2015. View Article : Google Scholar : PubMed/NCBI
4	Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al: Relation between microRNA expression and progression and prognosis of gastric cancer: A microRNA expression analysis. Lancet Oncol. 11:136–146. 2010. View Article : Google Scholar : PubMed/NCBI
5	Terry MB, Gaudet MM and Gammon MD: The epidemiology of gastric cancer. Semin Radiat Oncol. 12:111–127. 2002. View Article : Google Scholar : PubMed/NCBI
6	Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J, Savastano B, Mabilia A, et al: Treatment of gastric cancer. World J Gastroenterol. 20:1635–1649. 2014. View Article : Google Scholar : PubMed/NCBI
7	Hammond SM: MicroRNAs as oncogenes. Curr Opin Genet Dev. 16:4–9. 2006. View Article : Google Scholar : PubMed/NCBI
8	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
9	Macfarlane LA and Murphy PR: MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics. 11:537–561. 2010. View Article : Google Scholar : PubMed/NCBI
10	Wu G, Zheng K, Xia S, Wang Y, Meng X, Qin X and Cheng Y: MicroRNA-655-3p functions as a tumor suppressor by regulating ADAM10 and β-catenin pathway in Hepatocellular Carcinoma. J Exp Clin Cancer Res. 35:892016. View Article : Google Scholar : PubMed/NCBI
11	Chen XF and Liu Y: MicroRNA-744 inhibited cervical cancer growth and progression through apoptosis induction by regulating Bcl-2. Biomed Pharmacother. 81:379–387. 2016. View Article : Google Scholar : PubMed/NCBI
12	Sheng W, Chen Y, Gong Y, Dong T, Zhang B and Gao W: miR-148a inhibits self-renewal of thyroid cancer stem cells via repressing INO80 expression. Oncol Rep. 36:3387–3396. 2016. View Article : Google Scholar : PubMed/NCBI
13	Wang L and Yu P: miR-300 promotes proliferation and EMT-mediated colorectal cancer migration and invasion by targeting p53. Oncol Rep. 36:3225–3232. 2016. View Article : Google Scholar : PubMed/NCBI
14	Duan J, Zhang H, Qu Y, Deng T, Huang D, Liu R, Zhang L, Bai M, Zhou L, Ying G, et al: Onco-miR-130 promotes cell proliferation and migration by targeting TGFβR2 in gastric cancer. Oncotarget. 7:44522–44533. 2016. View Article : Google Scholar : PubMed/NCBI
15	Farooqi AA, Rehman ZU and Muntane J: Antisense therapeutics in oncology: Current status. Onco Targets Ther. 7:2035–2042. 2014. View Article : Google Scholar : PubMed/NCBI
16	Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
17	Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C and Croce CM: MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 297:1901–1908. 2007. View Article : Google Scholar : PubMed/NCBI
18	Qu Y, Zhang H, Duan J, Liu R, Deng T, Bai M, Huang D, Li H, Ning T, Zhang L, et al: MiR-17-5p regulates cell proliferation and migration by targeting transforming growth factor-beta receptor 2 in gastric cancer. Oncotarget. 7:33286–33296. 2016. View Article : Google Scholar : PubMed/NCBI
19	Yan M, Li X, Tong D, Han C, Zhao R, He Y and Jin X: miR-136 suppresses tumor invasion and metastasis by targeting RASAL2 in triple-negative breast cancer. Oncol Rep. 36:65–71. 2016. View Article : Google Scholar : PubMed/NCBI
20	Yang Y, Wu J, Guan H, Cai J, Fang L, Li J and Li M: MiR-136 promotes apoptosis of glioma cells by targeting AEG-1 and Bcl-2. FEBS Lett. 586:3608–3612. 2012. View Article : Google Scholar : PubMed/NCBI
21	Chen W, Yang Y, Chen B, Lu P, Zhan L, Yu Q, Cao K and Li Q: MiR-136 targets E2F1 to reverse cisplatin chemosensitivity in glioma cells. J Neurooncol. 120:43–53. 2014. View Article : Google Scholar : PubMed/NCBI
22	Shen S, Yue H, Li Y, Qin J, Li K, Liu Y and Wang J: Upregulation of miR-136 in human non-small cell lung cancer cells promotes Erk1/2 activation by targeting PPP2R2A. Tumour Biol. 35:631–640. 2014. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Li Y, Cui J, Zhang CH, Yang DJ, Chen JH, Zan WH, Li B, Li Z and He YL: High-expression of DJ-1 and loss of PTEN associated with tumor metastasis and correlated with poor prognosis of gastric carcinoma. Int J Med Sci. 10:1689–1697. 2013. View Article : Google Scholar : PubMed/NCBI
25	Zheng T, Meng X, Wang J, Chen X, Yin D, Liang Y, Song X, Pan S, Jiang H and Liu L: PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice. J Cell Biochem. 111:218–228. 2010. View Article : Google Scholar : PubMed/NCBI
26	Zhang LL, Liu J, Lei S, Zhang J, Zhou W and Yu HG: PTEN inhibits the invasion and metastasis of gastric cancer via downregulation of FAK expression. Cell Signal. 26:1011–1020. 2014. View Article : Google Scholar : PubMed/NCBI
27	He RF, Hu ZL and Wen JF: Biological implication of PTEN gene expression in human gastric cancer and related molecular mechanisms. Zhonghua Bing Li Xue Za Zhi. 36:324–328. 2007.(In Chinese). PubMed/NCBI
28	Sachdeva M and Mo YY: miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Transl Res. 2:170–180. 2010.PubMed/NCBI
29	Wu D, Niu X, Pan H, Zhou Y, Zhang Z, Qu P and Zhou J: Tumor-suppressing effects of microRNA-429 in human renal cell carcinoma via the downregulation of Sp1. Oncol Lett. 12:2906–2911. 2016. View Article : Google Scholar : PubMed/NCBI
30	Christgen M, Länger F and Kreipe H: Histological grading of breast cancer. Pathologe. 37:328–336. 2016.(In German). View Article : Google Scholar : PubMed/NCBI
31	Zhao H, Liu S, Wang G, Wu X, Ding Y, Guo G, Jiang J and Cui S: Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer. Oncol Rep. 33:591–598. 2015. View Article : Google Scholar : PubMed/NCBI
32	Yu Z, Ni L, Chen D, Zhang Q, Su Z, Wang Y, Yu W, Wu X, Ye J, Yang S, et al: Identification of miR-7 as an oncogene in renal cell carcinoma. J Mol Histol. 44:669–677. 2013. View Article : Google Scholar : PubMed/NCBI
33	Loures LF, Candido EB, Vidigal PV, Seabra MA, Marco LA and Silva-Filho AL: PTEN expression in patients with carcinoma of the cervix and its association with p53, Ki-67 and CD31. Rev Bras Ginecol Obstet. 36:205–210. 2014. View Article : Google Scholar : PubMed/NCBI
34	de Araujo WM, Robbs BK, Bastos LG, de Souza WF, Vidal FC, Viola JP and Morgado-Diaz JA: PTEN overexpression cooperates with lithium to reduce the malignancy and to increase cell death by apoptosis via PI3K/Akt suppression in colorectal cancer cells. J Cell Biochem. 117:458–469. 2016. View Article : Google Scholar : PubMed/NCBI
35	Zhou YH, Tan F, Hess KR and Yung WK: The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: Relationship to tumor grade and survival. Clin Cancer Res. 9:3369–3375. 2003.PubMed/NCBI
36	Koksal IT, Yasar D, Dirice E, Usta MF, Karauzum S, Luleci G, Baykara M and Sanlioglu S: Differential PTEN protein expression profiles in superficial versus invasive bladder cancers. Urol Int. 75:102–106. 2005. View Article : Google Scholar : PubMed/NCBI
37	Mithal P, Allott E, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J, Younus A, Sangale Z, Lanchbury JS, et al: PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer. Int J Urol. 21:1209–1214. 2014. View Article : Google Scholar : PubMed/NCBI
38	Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP and Mak TW: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 95:29–39. 1998. View Article : Google Scholar : PubMed/NCBI
39	Mukhopadhyay UK, Mooney P, Jia L, Eves R, Raptis L and Mak AS: Doubles game: Src-Stat3 versus p53-PTEN in cellular migration and invasion. Mol Cell Biol. 30:4980–4995. 2010. View Article : Google Scholar : PubMed/NCBI
40	Waite KA and Eng C: Protean PTEN: Form and function. Am J Hum Genet. 70:829–844. 2002. View Article : Google Scholar : PubMed/NCBI
41	Nogueira C, Kim KH, Sung H, Paraiso KH, Dannenberg JH, Bosenberg M, Chin L and Kim M: Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene. 29:6222–6232. 2010. View Article : Google Scholar : PubMed/NCBI
42	Lee H, Choi SK and Ro JY: Overexpression of DJ-1 and HSP90alpha, and loss of PTEN associated with invasive urothelial carcinoma of urinary bladder: Possible prognostic markers. Oncol Lett. 3:507–512. 2012.PubMed/NCBI
43	Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Tsuneyama K and Takano Y: Low expression of FHIT and PTEN correlates with malignancy of gastric carcinomas: Tissue-array findings. Appl Immunohistochem Mol Morphol. 15:432–440. 2007. View Article : Google Scholar : PubMed/NCBI
44	Ahn HS, Kim SH, Kodera Y and Yang HK: Gastric cancer staging with radiologic imaging modalities and UICC staging system. Dig Surg. 30:142–149. 2013. View Article : Google Scholar : PubMed/NCBI